TG TherapeuticsTGTX

• Phase 3재발성 다발성 경화증 대상 유블리툭시맙 피하주사 제형 임상진행 중A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
  59%
• Phase ?브리움비 재발성 다발성경화증 실사용 임상모집 중A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  59%
• Phase 3재발성 다발성 경화증 환자 대상 유블리툭시맙 연장 임상진행 중An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
  59%
• Phase ?브륨비(우블리툭시맙) 모유 내 잔류 및 농도 평가 임상모집 중A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
  59%
• Phase 3유블리툭시맙 투여 용법 변경 안전성 및 효과 임상모집 중Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
  59%
• Phase ?다발성 경화증 약물 브리움비의 임산부·태아 안전성 연구모집 중A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
  80%
• Phase 2소아 다발성 경화증 치료제 우블리툭시맙 임상시작 전Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
  71%
• Phase 1B세포 자가면역질환 대상 CAR-T 치료제 Azer-cel 임상모집 중A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
  48%
• Phase 2다발성 경화증 우블리툭시맙 피하주사 제형 비교 임상시작 전A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
  40%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.